Tue, October 3, 2017
Mon, October 2, 2017
Fri, September 29, 2017

Terence Flynn Upgraded (ALNY) to Strong Buy on, Oct 2nd, 2017

Terence Flynn of Goldman Sachs, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Strong Buy on, Oct 2nd, 2017.

Terence has made no other calls on ALNY in the last 4 months.



There are 7 other peers that have a rating on ALNY. Out of the 7 peers that are also analyzing ALNY, 2 agree with Terence's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Paul Matteis of "Leerink Swann" Maintained at Hold with Increased Target to $112 on, Thursday, September 21st, 2017
  • David Lebovitz of "Morgan Stanley" Maintained at Hold with Increased Target to $101 on, Thursday, September 21st, 2017


These are the ratings of the 5 analyists that currently disagree with Terence


  • Do Kim of "BMO Capital" Maintained at Buy with Increased Target to $134 on, Friday, September 22nd, 2017
  • Geoff Meacham of "Barclays" Maintained at Buy with Increased Target to $127 on, Thursday, September 21st, 2017
  • Alan Carr of "Needham" Maintained at Strong Buy with Increased Target to $125 on, Thursday, September 21st, 2017
  • Alethia Young of "Credit Suisse" Maintained at Buy with Increased Target to $123 on, Thursday, September 21st, 2017
  • Christopher Marai of "Nomura" Initiated at Sell and Held Target at $56 on, Friday, September 15th, 2017